CervoMed Inc. (CRVO) 8-K Summary (Nov 4, 2025)

CervoMed announced a significant regulatory development concerning its lead candidate, neflamapimod.

• Key Event: Received written feedback from the FDA regarding the proposed Phase 3 clinical trial protocol.
• Indication: Treatment for patients with dementia with Lewy bodies (DLB).
• Impact: The FDA feedback shows alignment on key aspects of the Phase 3 design, moving the company closer to initiating pivotal studies and “Advancing Towards Registration.”

This alignment de-risks the pathway to the pivota